KCNIP2 (Potassium Voltage-Gated Channel Interacting Protein 2) encodes a calcium-binding protein that serves as an accessory subunit for Kv4 voltage-gated potassium channels. KCNIP2 (also known as KChIP2) is a critical modulator of neuronal excitability, cardiac repolarization, and has been implicated in neurodegenerative diseases through its effects on Kv4 channel function and calcium-dependent signaling pathways[1].
| Property | Value |
|---|---|
| Gene Symbol | KCNIP2 |
| Full Name | Potassium Voltage-Gated Channel Interacting Protein 2 |
| Chromosomal Location | 10q23.3 |
| NCBI Gene ID | 30818 |
| Ensembl ID | ENSG00000116096 |
| UniProt ID | Q9H0Y9 |
| Encoded Protein | KCNIP2 (KChIP2) |
| Protein Family | KCNIP family (EF-hand calcium-binding proteins) |
| Molecular Weight | ~28 kDa |
The KCNIP2 gene is located on chromosome 10q23.3 and encodes a protein with multiple isoforms generated through alternative splicing. The gene contains multiple EF-hand calcium-binding domains that enable calcium-dependent regulation of Kv4 channels.
KCNIP2 exhibits a distinct expression pattern:
KCNIP2 has multiple isoforms with distinct subcellular localizations and functions:
KCNIP2 is a critical accessory subunit for Kv4 channels (Kv4.1, Kv4.2, Kv4.3), which mediate the transient outward potassium current (IA) important for neuronal excitability:
As an EF-hand calcium-binding protein, KCNIP2 participates in calcium-dependent signaling cascades:
Kv4 channels are critical for:
KCNIP2 and related KCNIP proteins are implicated in Alzheimer's disease through several mechanisms:
Neuronal hyperexcitability: Tau pathology leads to Kv4.2 depletion and dendritic hyperexcitability in AD models[2]. While KCNIP2 specifically hasn't been studied in detail, the Kv4 channel complex is affected.
Kv4 channel dysfunction: Voltage-gated potassium channels are affected by oxidative stress in aging and neurodegeneration[3].
Resilience signatures: Single-cell omics studies identified KCNIP4 (a related family member) as associated with resilient neurons in AD[4], suggesting KCNIP family members may play protective roles.
Neuronal excitability: Loss of DPP6 (another Kv4 accessory protein) increases risk for early-onset Alzheimer's through neuronal excitability dysfunction[5]. KCNIP2 may have similar effects.
Kv4 channel blockade: Kv4 channel blockade in the striatum reduces motor and neuropsychiatric symptoms in PD models[6], suggesting Kv4/KCNIP2 complex may be a therapeutic target.
Dopaminergic signaling: Kv4 channels regulate dopaminergic neuron excitability and could influence PD pathogenesis.
Non-motor symptoms: KCNIP2 dysfunction may contribute to neuropsychiatric symptoms in PD.
Altered expression: KCNIP2 expression is altered in epileptic tissue, potentially contributing to neuronal hyperexcitability.
Channel dysfunction: Kv4 channel dysregulation is implicated in seizure susceptibility.
Therapeutic target: KCNIP2 modulators may have anti-epileptic potential.
KCNIP2 mutations are associated with cardiac arrhythmias:
KCNIP2 is involved in sensory neuron excitability and pain signaling:
KCNIP2 serves as a molecular marker for OFF-transient alpha retinal ganglion cells[9], which are involved in visual processing and may be affected in retinal degenerations.
Kv4 channel dysfunction can contribute to excitotoxic cell death:
KCNIP proteins may be affected by oxidative stress in neurodegeneration:
Kv4 channels regulate synaptic plasticity:
KCNIP2 may interact with mitochondrial dysfunction in neurodegeneration:
The neuroinflammatory environment in neurodegenerative diseases affects KCNIP2:
KCNIP2 forms a stoichiometric complex with Kv4 α-subunits:
The Kv4 channel complex includes multiple auxiliary subunits:
KCNIP2 interacts with multiple signaling pathways:
KCNIP2 genetic variants have been associated with:
Multiple pharmaceutical companies have developed Kv4 modulators:
KCNIP2-based therapies may be combined with:
While no KCNIP2-targeted therapies are currently approved, the protein represents a potential target for:
Kcnip2 knockout mice have been generated and characterized:
Transgenic overexpression models have been developed to study:
KCNIP2 has been studied in various animal models:
KCNIP2 encodes a critical accessory subunit for Kv4 voltage-gated potassium channels, modulating neuronal and cardiac excitability. The protein has been implicated in Alzheimer's disease, Parkinson's disease, epilepsy, and cardiac arrhythmias through its effects on Kv4 channel function. While specific research on KCNIP2 in neurodegeneration is limited, the broader literature on Kv4 channels and related KCNIP family members supports a role in neuronal excitability dysfunction in AD and PD. KCNIP2 represents a potential therapeutic target for modulating neuronal excitability in neurodegenerative diseases.
K(V) Channel-Interacting Proteins in the Neurological and Cardiovascular Systems. ↩︎
Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease. ↩︎
Therapeutic role of voltage-gated potassium channels in age-related neurodegenerative diseases. ↩︎
Molecular Signatures of Resilience to Alzheimer's Disease in Neocortical Layer 4 Neurons. ↩︎
Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. ↩︎
Kv4 channel blockade reduces motor and neuropsychiatric symptoms in rodent models of Parkinson's disease. ↩︎
Inhibitory Kcnip2 neurons of the spinal dorsal horn control behavioral sensitivity to environmental cold. ↩︎
OFF-transient alpha RGCs mediate looming triggered innate defensive response. ↩︎